Recent Updates
Recently added Catalysts
KLRS Positive Sentiment

Kalaris to Present at Stifel 2025 Annual Healthcare Conference

Key Takeaway: Kalaris Therapeutics will present at the Stifel 2025 Annual Healthcare Conference on November 13, 2025. CEO Andrew Oxtoby and CMO Matthew Feinsod will speak from 3:20 to 3:50 PM ET. The company aims to address major unmet needs in retinal disease treatments. One-on-one meetings will also be available during the event.

Market Sentiment Analysis

POSITIVE FACTORS

  • Kalaris is presenting at a notable healthcare conference.
  • Management will engage in one-on-one meetings with interested parties.
  • The company focuses on treatments for prevalent retinal diseases.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+359%
120-day peak, hindsight
Typical move
9.9%
average across 3 past catalysts
Cash runway
~23 mo
Low dilution risk
Lead asset
Posoleucel
Phase 3 · Adenovirus Infection

Full Press Release Details

PALO ALTO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will present at the upcoming Stifel 2025 Annual Healthcare Conference.
Details:
• Type: Company presentation
• Speakers: Andrew Oxtoby, Chief Executive Officer & Matthew Feinsod, Chief Medical Officer
• Date: Thursday, November 13, 2025
• Time: 3:20 – 3:50pm ET
• Location: Lotte New York Palace Hotel, New York, NY
Kalaris management will be available for one-on-one meetings during the conference. Interested parties should contact their conference representative to arrange a meeting.
About Kalaris
Kalaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases with major unmet medical needs. Founded by renowned scientist Dr. Napoleone Ferrara, whose pioneering research led to the development of anti-VEGF therapy, the company is committed to advancing novel therapeutic approaches for patients with sight-threatening retinal conditions such as neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).
For more information, visit www.kalaristx.com.

Frequently Asked Questions

When will Kalaris present at the conference?

Kalaris will present on November 13, 2025.

Who will speak at the Kalaris presentation?

CEO Andrew Oxtoby and CMO Matthew Feinsod will speak.

Where is the Stifel Conference held?

The conference will be at the Lotte New York Palace Hotel.

What is Kalaris focused on developing?

Kalaris develops treatments for prevalent retinal diseases.

Last updated: Oct 30, 2025